CN111675761B - 柄蛋白-4结合蛋白及其使用方法 - Google Patents

柄蛋白-4结合蛋白及其使用方法 Download PDF

Info

Publication number
CN111675761B
CN111675761B CN202010492265.3A CN202010492265A CN111675761B CN 111675761 B CN111675761 B CN 111675761B CN 202010492265 A CN202010492265 A CN 202010492265A CN 111675761 B CN111675761 B CN 111675761B
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010492265.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111675761A (zh
Inventor
K·J·M·莫里森
F·多纳特
P·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to CN202010492265.3A priority Critical patent/CN111675761B/zh
Publication of CN111675761A publication Critical patent/CN111675761A/zh
Application granted granted Critical
Publication of CN111675761B publication Critical patent/CN111675761B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202010492265.3A 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法 Active CN111675761B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010492265.3A CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762515454P 2017-06-05 2017-06-05
US62/515,454 2017-06-05
CN201880049820.6A CN111051345A (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法
CN202010492265.3A CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法
PCT/US2018/035840 WO2018226578A1 (en) 2017-06-05 2018-06-04 Nectin-4-binding proteins and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880049820.6A Division CN111051345A (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Publications (2)

Publication Number Publication Date
CN111675761A CN111675761A (zh) 2020-09-18
CN111675761B true CN111675761B (zh) 2023-10-20

Family

ID=64566092

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010492265.3A Active CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法
CN201880049820.6A Pending CN111051345A (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880049820.6A Pending CN111051345A (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Country Status (10)

Country Link
US (1) US11292837B2 (2)
EP (1) EP3635013A4 (2)
JP (1) JP7168590B2 (2)
KR (1) KR102723905B1 (2)
CN (2) CN111675761B (2)
BR (1) BR112019025513A2 (2)
CA (1) CA3065514A1 (2)
MX (1) MX2019014318A (2)
TW (1) TWI870338B (2)
WO (1) WO2018226578A1 (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN110904074B (zh) * 2019-05-31 2020-12-01 江南大学 一种脂肪酶突变体及其在去污方面的应用
US12398206B2 (en) 2019-10-07 2025-08-26 Université D'aixmarseille Antibodies having specificity for nectin-4 and uses thereof
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
EP4096717B1 (en) 2020-01-31 2024-12-11 Innate Pharma Treatment of cancer
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
CN115768798A (zh) * 2020-06-18 2023-03-07 生物蛋白有限公司 条件活性抗粘附分子-4(nectin-4)抗体
MX2022016232A (es) * 2020-06-19 2023-03-14 Agensys Inc Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
EP4215546A4 (en) * 2020-09-16 2025-02-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-NECTIN-4 ANTIBODY, CONJUGATE THEREOF AND USE THEREOF
MX2023005873A (es) * 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
TW202302649A (zh) * 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
EP4463483A4 (en) * 2022-01-12 2025-05-21 Navi Bio-Therapeutics, Inc. ANTIBODY SPECIFIC TO NECTIN CELL ADHESION MOLECULE 4 AND USES THEREOF
US20250205353A1 (en) 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
EP4310101A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibodies and antibody-drug conjugates
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
WO2024251260A1 (zh) 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203053A2 (en) * 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268476A1 (en) 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203053A2 (en) * 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dean O Campbell等.Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.《Mol Imaging Biol 》.2016,第第18卷卷(第第18卷期),第768-775页. *

Also Published As

Publication number Publication date
TWI870338B (zh) 2025-01-21
RU2019144030A (ru) 2021-07-09
JP7168590B2 (ja) 2022-11-09
US20200231670A1 (en) 2020-07-23
BR112019025513A2 (pt) 2020-06-23
KR102723905B1 (ko) 2024-10-31
WO2018226578A8 (en) 2019-05-31
CN111051345A (zh) 2020-04-21
KR20200024788A (ko) 2020-03-09
EP3635013A4 (en) 2021-02-24
MX2019014318A (es) 2020-08-13
JP2020522261A (ja) 2020-07-30
CN111675761A (zh) 2020-09-18
TW201902922A (zh) 2019-01-16
EP3635013A1 (en) 2020-04-15
WO2018226578A1 (en) 2018-12-13
US11292837B2 (en) 2022-04-05
RU2019144030A3 (2) 2021-12-28
CA3065514A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CN111675761B (zh) 柄蛋白-4结合蛋白及其使用方法
US12378312B2 (en) Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof
CN108289953B (zh) Pd-1结合蛋白及其使用方法
TWI388568B (zh) 抗ｆｇｆ１９抗體及其使用方法
TW202028237A (zh) SIRPα結合蛋白及其使用方法
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
CA2887129A1 (en) Anti-c16orf54 antibodies and methods of use thereof
US20210380675A1 (en) Il-36 antibodies and uses thereof
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
RU2805252C2 (ru) Белки, связывающие нектин-4, и способы их применения
HK40037283A (en) Nectin-4 binding proteins and methods of use thereof
HK40037283B (zh) 柄蛋白-4结合蛋白及其使用方法
HK40026608A (en) Nectin-4 binding proteins and methods of use thereof
KR20240154675A (ko) Btn1a1 결합 단백질 및 이의 이용 방법
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825B (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037283

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant